2021-04-12
March 4, 2021
Issuance of U.S. Patent No. US 10,909,682 B2 Further Bolsters Imsight’s Intellectual Patent Portfolio
We are pleased to announce our latest patent focusing on the method and device for detecting pulmonary nodules in CT images. This has been a great milestone for Imsight to enhance the breadth and depth of our patent portfolio.
Being first to market, Imsight’s role as a pioneer is to offer innovative solutions such as Lung-Sight that can reach the marketplace at first, and provide a truly unique experience where no else can be found. Imsight will continuously maintain our competitive advantages by improving and customizing our products that suit the needs of the medical field and creating a better future for the healthcare industry.
▲ United States Patent (Patent No.: US 10,909,682 B2).
Imsight Technology Co., Limited, an AI-led, medical imaging company focused on identifying, developing and commercializing innovative and differentiated medical solutions to address significant unmet needs in Radiology and Pathology, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. US 10,909,682 B2, which is directed to methods and devices related to the detection of nodules in computed tomography image and storage medium.
U.S. Patent No. US 10,909,682 B2 covers the use of automatically detecting pulmonary nodules in CT images, such as obtaining a CT image to be detected, performing a pixel segmentation processing on the CT image through a prestored 3D convolutional neural pixel segmentation network etc. The Patent contains 18 claims and expires in June 2039.
“The continued growth of the patent portfolio from which we exclusively licensed is highly pleasing to us. Mr Chapman Lee, Director of Imsight, said, "The issuance of this patent is another step in the growth of a comprehensive patent portfolio relating to the identification of nodules in CT images.”
Please click Here for more information.
